Takeda and Insilico Team Up on AI Drugs | Tech News

Takeda teams up with Insilico Medicine to supercharge drug discovery using AI, granting exclusive rights to new medicines while Insilico handles AI-driven target identification and molecule design. This marks Takeda’s latest leap into AI-powered research, following a similar cancer-focused deal with Iambic. Insilico, already in clinical trials with an AI-generated lung drug and backed by major partners like Eli Lilly and SK Biopharmaceuticals, sees its stock soar after the announcement — signaling a bold industry shift toward AI to accelerate next-gen treatments. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/86f928b8f3617612